These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26559576)

  • 1. Targeting Stem Cells in Chronic Myeloid Leukemia with a PPAR-γ Agonist.
    Egan JM
    N Engl J Med; 2015 Nov; 373(20):1973-5. PubMed ID: 26559576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
    Gambacorti-Passerini C; Piazza R
    JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate.
    Maral S; Bakanay SM; Yikilmaz AS; Dilek I
    J Cancer Res Ther; 2018; 14(6):1431-1433. PubMed ID: 30488870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
    Eskazan AE; Tiribelli M
    Leuk Res; 2018 Nov; 74():55-56. PubMed ID: 30296661
    [No Abstract]   [Full Text] [Related]  

  • 5. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
    Gniot M; Wasilewska EM; Lewandowski K
    Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia.
    Yun S; Vincelette ND; Abraham I
    JAMA Oncol; 2016 Jun; 2(6):828-9. PubMed ID: 27281623
    [No Abstract]   [Full Text] [Related]  

  • 7. Resolution of Roth spots in chronic myeloid leukaemia after treatment with imatinib.
    Docherty SM; Reza M; Turner G; Bowles K
    Br J Haematol; 2015 Sep; 170(6):744. PubMed ID: 26119417
    [No Abstract]   [Full Text] [Related]  

  • 8. Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
    Angriman F; Gutierrez Acevedo MN; Rossi MS; Gimenez Conca AD; Otero V; Arbelbide JA; Michelángelo H
    Turk J Haematol; 2015 Jun; 32(2):193-4. PubMed ID: 26316496
    [No Abstract]   [Full Text] [Related]  

  • 9. The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis.
    Eskazan AE
    J Med Econ; 2018 Jul; 21(7):709-711. PubMed ID: 29673265
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.
    Di Felice E; Roncaglia F; Venturelli F; Mangone L; Luminari S; Cirilli C; Carrozzi G; Giorgi Rossi P
    BMC Cancer; 2018 Nov; 18(1):1069. PubMed ID: 30400842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukaemia.
    Kaur U; Gambhir IS; Khare VR; Singh A; Chakrabarti SS
    Br J Haematol; 2020 Jul; 190(1):e51-e53. PubMed ID: 32400888
    [No Abstract]   [Full Text] [Related]  

  • 12. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
    Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
    Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
    [No Abstract]   [Full Text] [Related]  

  • 13. The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.
    Raanani P
    Acta Haematol; 2016; 135(3):131-2. PubMed ID: 26535978
    [No Abstract]   [Full Text] [Related]  

  • 14. Pediatric chronic myeloid leukemia with myeloid blast crisis and complex karyotype at presentation.
    Sazawal S; Singh K; Chhikara S; Chaubey R; Mishra P; Seth T; Saxena R
    Indian J Cancer; 2020; 57(3):343-345. PubMed ID: 32769290
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What Happens When Imatinib Goes Generic?
    McDougall J; Ramsey SD; Radich J
    J Natl Compr Canc Netw; 2016 Feb; 14(2):128-31. PubMed ID: 26850483
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Danisz K; Blasiak J
    Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors.
    Maeda Y; Okamoto A; Kawaguchi SI; Konishi A; Yamamoto K; Eguchi G; Kanai Y; Yamaguchi T
    Acta Haematol; 2017; 138(3):140-142. PubMed ID: 28869927
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.